TABLE 1.
Patient characteristics for ACC and non-ACC cohorts
| Characteristic | ACC | Non-ACC |
|---|---|---|
| No(%) | No(%) | |
| 18 (100%) | 18 (100%) | |
|
| ||
| Age | ||
| Median | 50 | 59 |
| Range | (26–80) | (29–76) |
|
| ||
| Gender | ||
| Male | 13 (72%) | 10 (56%) |
| Female | 5 (28%) | 8 (44%) |
|
| ||
| Performance status | ||
| ECOG 0–1 | 17 (94%) | 18 (100%) |
| ECOG2 | 1 (6%) | 0 (0%) |
|
| ||
| Histology | ||
| Adenoid cystic carcinoma | 18 (100%) | - |
| Acinic cell carcinoma | - | 2 (11%) |
| High grade adenocarcinoma | - | 6 (33%) |
| Mucoepidermoid | - | 2 (11%) |
| Myoepithelial carcinoma | - | 1 (6%) |
| Salivary duct carcinoma | - | 3 (17%) |
| Salivary adenocarcinoma | - | 3 (17%) |
|
| ||
| Primary site | ||
| Parotid | 2 (11%) | 11 (61%) |
| Sublingual | 2 (11%) | 1 (6%) |
| Submandibular | 1 (6%) | 2 (11%) |
| Buccal mucosa | - | 1 (6%) |
| Tongue | - | 2 (11%) |
| Gingiva | 1 (6%) | - |
| Floor of the mouth | 1 (6%) | - |
| Sinuses | 2 (11%) | - |
| Trachea | 2 (11%) | - |
| Lung | 2 (11%) | - |
| Palate | 4 (22%) | - |
| Skin of ear | 1 (6%) | - |
| Unknown Primary Site | - | 1 (6%) |
|
| ||
| Previous Systemic Therapies, | ||
| Yes | 6 (33%) | 10 (56%) |
| No | 12 (67%) | 8 (44%) |
| Median (range) | 3 (1–5) | 2 (1–6) |
|
| ||
| Prior Surgery | ||
| Yes | 17 (94%) | 15 (83%) |
| No | 1 (6%) | 3 (17%) |
|
| ||
| Prior Radiation Therapy | ||
| Yes | 15 (83%) | 13 (72%) |
| No | 3 (17%) | 5 (28%) |
|
| ||
| EGFR Status* | ||
| Positive (2+ or 3+) | 6 (38%) | 4 (24%) |
| Negative (0 or 1+) | 10 (63%) | 13 (76%) |
|
| ||
| HER2 Status* | ||
| Positive (2+ or 3+) | 0 (0%) | 9 (50%) |
| Negative (0 or 1+) | 16 (100%) | 9 (50%) |
*
Tissue available for EGFR in 16 ACC and 17 non-ACC, and for HER2 in 16 ACC and 18 non-ACC